Chelsea’s highly‑rated winger Mykhailo Mudryk has taken his case to the Court of Arbitration for Sport (CAS) after the English Football Association imposed a four‑year ban for a doping violation. The appeal was formally lodged on 25 February, according to a confirmation from CAS. Neither the FA, Chelsea FC nor Mudryk’s legal representatives have offered any public comment on the matter. Mudryk arrived at Chelsea in January 2023, arriving from Ukrainian side Shakhtar Donetsk for a reported fee of £88 million.
His contract still contains five years of remaining obligations, meaning the potential sanction could have a profound impact on both his career and the club’s long‑term plans. The substance that triggered the ban was identified as meldonium, a medication that is prohibited under the World Anti‑Doping Agency’s (WADA) rules. Mudryk maintains that the positive result was the result of an accidental contamination that occurred while he was representing Ukraine on international duty in October 2024.
He insists that he never knowingly consumed a banned product. The chain of events began when the FA provisionally suspended Mudryk in December 2024 after the initial laboratory analysis flagged a prohibited substance in his sample.
In a statement released that same month, Mudryk described the outcome as “a complete shock” and reaffirmed his innocence, stating that he had done nothing to merit such a sanction. Chelsea launched an internal investigation shortly after the FA’s provisional suspension.
The club’s inquiry concluded that the 23‑year‑old had consistently denied any deliberate use of performance‑enhancing drugs and claimed to have never taken anything that would contravene anti‑doping regulations. The club’s official stance was to support Mudryk’s claim of innocence while allowing the governing bodies to complete their procedural review. Since his last appearance for Chelsea – a 2‑0 victory over German side Heidenheim in the UEFA Conference League on 28 November 2024, in which he also found the net – Mudryk has been absent from competitive action for roughly 18 months. During this period he has kept himself in shape by training with personal coaches away from Chelsea’s Cobham facilities, indicating a desire to remain ready for a possible return should the appeal be successful.
Sky Sports’ chief correspondent Kaveh Solhekol explained the limited information surrounding the case: “The only reason we know Mudryk has been banned by the Football Association is because it has been confirmed by CAS that he has appealed against it. The FA itself has remained silent, citing confidentiality. Chelsea and Mudryk’s lawyers have also refrained from commenting.” Solhekol added context about the timing of the test, noting that the sample was taken while Mudryk was on international duty, not during a club training session.
“The test returned a positive result for meldonium. He was provisionally suspended in December 2024 and formally charged with an anti‑doping violation the following June. Since then there has been virtually no public update until today.” If the CAS panel upholds the FA’s four‑year ban, Mudryk’s suspension would likely extend to the end of 2028, effectively sidelining him for the remainder of his current contract and potentially jeopardising the club’s substantial investment.
Such an outcome would be a severe setback for both the player, whose development has stalled, and Chelsea, which paid a premium price for his acquisition. The appeal process at CAS is expected to involve a detailed examination of the testing procedures, chain‑of‑custody documentation, and any evidence Mudryk can present to demonstrate inadvertent contamination.
Legal experts note that cases involving meldonium can be complex, as the substance’s pharmacokinetics and permissible therapeutic use thresholds have been subjects of debate within the anti‑doping community. While the final decision remains pending, Mudryk’s situation underscores the broader challenges athletes face when navigating anti‑doping regulations, especially when testing occurs during international fixtures where medical support and supplement control may differ from club environments.
The case also highlights the importance of rigorous sample handling and transparent communication between national associations, clubs, and anti‑doping agencies. Regardless of the outcome, Mudryk’s appeal will be closely watched by football fans, legal analysts, and anti‑doping officials alike, as it could set a precedent for how similar contamination claims are evaluated in the future. The next steps will involve the presentation of arguments before the CAS panel, after which a ruling is anticipated within several months. Until then, the player remains provisionally suspended, training independently, and hoping that his appeal will overturn the ban and allow him to resume his career at the highest level.